long term tirzepatide Associated with Lower POAG, OHT Risk Compared with Other GLP-1 Drugs Interesting finds - long term
Description
The research looked at the impact on outcomes triggered by a reduction in dose and a change to the prescribed weekly dose regimen, reflecting the imperfect adherence prevalent in real-world patients
They did say that this was occurring more frequently with the onset of the early period of use of the GLP-1, so the patients had been on it for a short period of time, so what dose were they on
Those who reached higher doses achieved weight loss comparable to trials
Persistent aches beyond 3 months warrant medical evaluation
These two medications are from the same class
